PEAK6’s BridgeBio Pharma BBIO Stock Holding History

PEAK6’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,600	Closed	-$98.8K	–	3002
2024 Q4	$98.8K	Buy	+3,600	New	+$93K	﹤0.01%	2719

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6's BBIO Position: Q1 2025 in Review

PEAK6 sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 3,600 shares — an estimated $98.8K sold.

PEAK6 first reported a position in BBIO in Q4 2024 and held it in 1 quarter. The position peaked at $98.8K in Q4 2024. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

PEAK6 reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
PEAK6 sold 3,600 BridgeBio Pharma shares in Q1 2025, an estimated $98.8K.
PEAK6 first reported a position in BridgeBio Pharma in Q4 2024 and held it in 1 quarter.
PEAK6's BridgeBio Pharma position peaked at $98.8K in Q4 2024.
304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.